This review focuses on the impact of human papillomavirus (HPV) oncogenes on DNA repair pathways with a particular focus on how these relationships change as productive HPV infections transition to malignant lesions. We made specific efforts to incorporate advances in the understanding of HPV and DNA damage repair over the last 4 years. We apologize for any articles that we missed in compiling this report.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732048 | PMC |
| http://dx.doi.org/10.1128/msphere.00427-23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mapping the HPV Landscape in South African Women: A Systematic Review and Meta-Analysis of Viral Genotypes, Microbiota, and Immune Signals.
Viruses
December 2024
Discipline of Genetics, School of Life Sciences, University of KwaZulu-Natal, Pietermaritzburg 3209, South Africa.
This systematic review and meta-analysis evaluate human papillomavirus (HPV) prevalence, genotype distribution, and associations with cervicovaginal microbiota and cytokine profiles among South African women, where cervical cancer ranks as the second most common cancer. PubMed, SCOPUS, and Web of Science were searched for studies on HPV infection up to 21 September 2024. The pooled prevalence was estimated using a random-effects model, with subgroup analyses by province, sample type, and HIV status.
View Article and Find Full Text PDFIsothermal Nucleic Acid Amplification for Point-of-Care Primary Cervical Cancer Screening.
Viruses
November 2024
Department of Urology, North Hospital, CHU Saint Etienne, 42055 Saint Etienne, France.
Human Papillomavirus (HPV) infection is a significant global health concern linked to various cancers, particularly cervical cancer. Timely and accurate detection of HPV is crucial for effective management and prevention strategies. Traditional laboratory-based HPV testing methods often suffer from limitations such as long turnaround times, restricted accessibility, and the need for trained personnel, especially in resource-limited settings.
View Article and Find Full Text PDFStakeholder Consultation Workshop on the Perceived Value of Thermostable Vaccines to Relieve Program Barriers: A Case Study from Côte d'Ivoire.
Vaccines (Basel)
December 2024
PATH-Headquarters, Seattle, WA 98121, USA.
Background: Persistent inequities in access to vaccinations pose challenges for immunization programs worldwide. Innovations facilitating vaccine delivery, such as leveraging vaccine thermostability through a Controlled Temperature Chain (CTC), have emerged as a potential solution to increase coverage in low- and middle-income countries (LMICs) countries such as Côte d'Ivoire, reducing dependence on the cold chain and improving vaccine delivery efficiency. However, the added value of thermostable vaccines and their integration into national immunization programs is under-recognized by stakeholders.
View Article and Find Full Text PDFIdentifying the Gaps in Human Papillomavirus (HPV) Vaccine Uptake: An Exploratory Factor Analysis of Adults in Tennessee.
Vaccines (Basel)
December 2024
Department of Environmental, Agricultural & Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Human papillomavirus (HPV) remains the most prevalent sexually transmitted infection in the United States (U.S.).
View Article and Find Full Text PDFHPV Vaccines Among University Students: Understanding Barriers and Facilitators of Vaccine Uptake.
Vaccines (Basel)
December 2024
Department of Family, Population, and Preventative Medicine, Stony Brook Medicine, Stony Brook, NY 11794, USA.
Human papillomavirus (HPV) is the most common sexually transmitted infection and plays a significant role in cervical, penile, anal, vaginal, vulvar, and oropharyngeal cancers as well as non-cancerous genital warts and genital dysplasia. In the United States, there are approximately 46,000 new HPV-related cancers a year. There is an effective vaccine to prevent over 90% of these cancers and other HPV-related diseases; however, those that are aged 18-26 have the lowest vaccine rates among eligible age groups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!